Survival benefit of primary prevention implantable cardioverter- defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials

Paul L. Hess, Amy Laird, Rex Edwards, Gust H. Bardy, J. Thomas Bigger, Alfred E. Buxton, Arthur J. Moss, Kerry L. Lee, W. J. Hall, Richard Steinman, Paul Dorian, Al Hallstrom, Riccardo Cappato, Alan H. Kadish, Peter J. Kudenchuk, Daniel B. Mark, Sana M. Al-Khatib, Jonathan P. Piccini, Lurdes Y T Inoue, Gillian D. Sanders

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown. OBJECTIVE: To evaluate the effect of time from MI to randomization on mortality, rehospitalizations, and complications. METHODS: Individual data on patients enrolled in 9 primary prevention ICD trials were provided. Clinical trials were eligible for the current analysis if they enrolled patients with an MI more than 40 days prior to randomization to primary prevention ICD therapy vs usual care: Multicenter Automatic Defibrillator Implantation Trial I, Multicenter UnSustained Tachyardia Trial, Multicenter Automatic Defibrillator Implantation Trial II, and Sudden Cardiac Death in Heart Failure Trial. RESULTS: ICD recipients died less frequently than nonrecipients at 5 years across all subgroups of time from MI to randomization. In unadjusted Cox proportional hazards regression, a survival benefit was evident in most subgroups. Adjusted Bayesian Weibull survival modeling yielded hazard ratio (HR) 0.50, 95% posterior credible interval (PCI) 0.20-1.25 41-180 days after MI; HR 0.98, 95% PCI 0.37-2.37 181-365 days after MI; HR 0.22, 95% PCI 0.07- 0.59 >1-2 years after MI; HR 0.42, 95% PCI 0.17-0.90 >2-5 years after MI; HR 0.55, 95% PCI 0.25-1.15 >5-10 years after MI; and HR 0.48, 95% PCI 0.20-1.02 >10 years after MI. There was no evidence of an interaction between time from MI and all-cause mortality, rehospitalizations, or complications. CONCLUSIONS: In this meta-analysis, there was scant evidence that the efficacy of primary prevention ICD therapy depends on time to implantation more than 40 days after MI. Similarly, there was no evidence that the risks of rehospitalizations or complications depend on time more than 40 days after MI.

Original languageEnglish
Pages (from-to)828-835
Number of pages8
JournalHeart Rhythm
Volume10
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Implantable Defibrillators
Primary Prevention
Meta-Analysis
Myocardial Infarction
Clinical Trials
Survival
Therapeutics
Random Allocation
Defibrillators
Multicenter Studies
Mortality
Sudden Cardiac Death
Heart Failure

Keywords

  • Heart failure
  • Implantable cardioverter-defibrillator
  • Myocardial infarction
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Survival benefit of primary prevention implantable cardioverter- defibrillator therapy after myocardial infarction : Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. / Hess, Paul L.; Laird, Amy; Edwards, Rex; Bardy, Gust H.; Bigger, J. Thomas; Buxton, Alfred E.; Moss, Arthur J.; Lee, Kerry L.; Hall, W. J.; Steinman, Richard; Dorian, Paul; Hallstrom, Al; Cappato, Riccardo; Kadish, Alan H.; Kudenchuk, Peter J.; Mark, Daniel B.; Al-Khatib, Sana M.; Piccini, Jonathan P.; Inoue, Lurdes Y T; Sanders, Gillian D.

In: Heart Rhythm, Vol. 10, No. 6, 06.2013, p. 828-835.

Research output: Contribution to journalArticle

Hess, PL, Laird, A, Edwards, R, Bardy, GH, Bigger, JT, Buxton, AE, Moss, AJ, Lee, KL, Hall, WJ, Steinman, R, Dorian, P, Hallstrom, A, Cappato, R, Kadish, AH, Kudenchuk, PJ, Mark, DB, Al-Khatib, SM, Piccini, JP, Inoue, LYT & Sanders, GD 2013, 'Survival benefit of primary prevention implantable cardioverter- defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials', Heart Rhythm, vol. 10, no. 6, pp. 828-835. https://doi.org/10.1016/j.hrthm.2013.02.011
Hess, Paul L. ; Laird, Amy ; Edwards, Rex ; Bardy, Gust H. ; Bigger, J. Thomas ; Buxton, Alfred E. ; Moss, Arthur J. ; Lee, Kerry L. ; Hall, W. J. ; Steinman, Richard ; Dorian, Paul ; Hallstrom, Al ; Cappato, Riccardo ; Kadish, Alan H. ; Kudenchuk, Peter J. ; Mark, Daniel B. ; Al-Khatib, Sana M. ; Piccini, Jonathan P. ; Inoue, Lurdes Y T ; Sanders, Gillian D. / Survival benefit of primary prevention implantable cardioverter- defibrillator therapy after myocardial infarction : Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. In: Heart Rhythm. 2013 ; Vol. 10, No. 6. pp. 828-835.
@article{00648dceb1f74cc4903fc7535c21c400,
title = "Survival benefit of primary prevention implantable cardioverter- defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials",
abstract = "BACKGROUND: Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown. OBJECTIVE: To evaluate the effect of time from MI to randomization on mortality, rehospitalizations, and complications. METHODS: Individual data on patients enrolled in 9 primary prevention ICD trials were provided. Clinical trials were eligible for the current analysis if they enrolled patients with an MI more than 40 days prior to randomization to primary prevention ICD therapy vs usual care: Multicenter Automatic Defibrillator Implantation Trial I, Multicenter UnSustained Tachyardia Trial, Multicenter Automatic Defibrillator Implantation Trial II, and Sudden Cardiac Death in Heart Failure Trial. RESULTS: ICD recipients died less frequently than nonrecipients at 5 years across all subgroups of time from MI to randomization. In unadjusted Cox proportional hazards regression, a survival benefit was evident in most subgroups. Adjusted Bayesian Weibull survival modeling yielded hazard ratio (HR) 0.50, 95{\%} posterior credible interval (PCI) 0.20-1.25 41-180 days after MI; HR 0.98, 95{\%} PCI 0.37-2.37 181-365 days after MI; HR 0.22, 95{\%} PCI 0.07- 0.59 >1-2 years after MI; HR 0.42, 95{\%} PCI 0.17-0.90 >2-5 years after MI; HR 0.55, 95{\%} PCI 0.25-1.15 >5-10 years after MI; and HR 0.48, 95{\%} PCI 0.20-1.02 >10 years after MI. There was no evidence of an interaction between time from MI and all-cause mortality, rehospitalizations, or complications. CONCLUSIONS: In this meta-analysis, there was scant evidence that the efficacy of primary prevention ICD therapy depends on time to implantation more than 40 days after MI. Similarly, there was no evidence that the risks of rehospitalizations or complications depend on time more than 40 days after MI.",
keywords = "Heart failure, Implantable cardioverter-defibrillator, Myocardial infarction, Sudden cardiac death",
author = "Hess, {Paul L.} and Amy Laird and Rex Edwards and Bardy, {Gust H.} and Bigger, {J. Thomas} and Buxton, {Alfred E.} and Moss, {Arthur J.} and Lee, {Kerry L.} and Hall, {W. J.} and Richard Steinman and Paul Dorian and Al Hallstrom and Riccardo Cappato and Kadish, {Alan H.} and Kudenchuk, {Peter J.} and Mark, {Daniel B.} and Al-Khatib, {Sana M.} and Piccini, {Jonathan P.} and Inoue, {Lurdes Y T} and Sanders, {Gillian D.}",
year = "2013",
month = "6",
doi = "10.1016/j.hrthm.2013.02.011",
language = "English",
volume = "10",
pages = "828--835",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Survival benefit of primary prevention implantable cardioverter- defibrillator therapy after myocardial infarction

T2 - Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials

AU - Hess, Paul L.

AU - Laird, Amy

AU - Edwards, Rex

AU - Bardy, Gust H.

AU - Bigger, J. Thomas

AU - Buxton, Alfred E.

AU - Moss, Arthur J.

AU - Lee, Kerry L.

AU - Hall, W. J.

AU - Steinman, Richard

AU - Dorian, Paul

AU - Hallstrom, Al

AU - Cappato, Riccardo

AU - Kadish, Alan H.

AU - Kudenchuk, Peter J.

AU - Mark, Daniel B.

AU - Al-Khatib, Sana M.

AU - Piccini, Jonathan P.

AU - Inoue, Lurdes Y T

AU - Sanders, Gillian D.

PY - 2013/6

Y1 - 2013/6

N2 - BACKGROUND: Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown. OBJECTIVE: To evaluate the effect of time from MI to randomization on mortality, rehospitalizations, and complications. METHODS: Individual data on patients enrolled in 9 primary prevention ICD trials were provided. Clinical trials were eligible for the current analysis if they enrolled patients with an MI more than 40 days prior to randomization to primary prevention ICD therapy vs usual care: Multicenter Automatic Defibrillator Implantation Trial I, Multicenter UnSustained Tachyardia Trial, Multicenter Automatic Defibrillator Implantation Trial II, and Sudden Cardiac Death in Heart Failure Trial. RESULTS: ICD recipients died less frequently than nonrecipients at 5 years across all subgroups of time from MI to randomization. In unadjusted Cox proportional hazards regression, a survival benefit was evident in most subgroups. Adjusted Bayesian Weibull survival modeling yielded hazard ratio (HR) 0.50, 95% posterior credible interval (PCI) 0.20-1.25 41-180 days after MI; HR 0.98, 95% PCI 0.37-2.37 181-365 days after MI; HR 0.22, 95% PCI 0.07- 0.59 >1-2 years after MI; HR 0.42, 95% PCI 0.17-0.90 >2-5 years after MI; HR 0.55, 95% PCI 0.25-1.15 >5-10 years after MI; and HR 0.48, 95% PCI 0.20-1.02 >10 years after MI. There was no evidence of an interaction between time from MI and all-cause mortality, rehospitalizations, or complications. CONCLUSIONS: In this meta-analysis, there was scant evidence that the efficacy of primary prevention ICD therapy depends on time to implantation more than 40 days after MI. Similarly, there was no evidence that the risks of rehospitalizations or complications depend on time more than 40 days after MI.

AB - BACKGROUND: Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown. OBJECTIVE: To evaluate the effect of time from MI to randomization on mortality, rehospitalizations, and complications. METHODS: Individual data on patients enrolled in 9 primary prevention ICD trials were provided. Clinical trials were eligible for the current analysis if they enrolled patients with an MI more than 40 days prior to randomization to primary prevention ICD therapy vs usual care: Multicenter Automatic Defibrillator Implantation Trial I, Multicenter UnSustained Tachyardia Trial, Multicenter Automatic Defibrillator Implantation Trial II, and Sudden Cardiac Death in Heart Failure Trial. RESULTS: ICD recipients died less frequently than nonrecipients at 5 years across all subgroups of time from MI to randomization. In unadjusted Cox proportional hazards regression, a survival benefit was evident in most subgroups. Adjusted Bayesian Weibull survival modeling yielded hazard ratio (HR) 0.50, 95% posterior credible interval (PCI) 0.20-1.25 41-180 days after MI; HR 0.98, 95% PCI 0.37-2.37 181-365 days after MI; HR 0.22, 95% PCI 0.07- 0.59 >1-2 years after MI; HR 0.42, 95% PCI 0.17-0.90 >2-5 years after MI; HR 0.55, 95% PCI 0.25-1.15 >5-10 years after MI; and HR 0.48, 95% PCI 0.20-1.02 >10 years after MI. There was no evidence of an interaction between time from MI and all-cause mortality, rehospitalizations, or complications. CONCLUSIONS: In this meta-analysis, there was scant evidence that the efficacy of primary prevention ICD therapy depends on time to implantation more than 40 days after MI. Similarly, there was no evidence that the risks of rehospitalizations or complications depend on time more than 40 days after MI.

KW - Heart failure

KW - Implantable cardioverter-defibrillator

KW - Myocardial infarction

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=84883253090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883253090&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2013.02.011

DO - 10.1016/j.hrthm.2013.02.011

M3 - Article

C2 - 23416381

AN - SCOPUS:84883253090

VL - 10

SP - 828

EP - 835

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 6

ER -